MedTrace Logo

Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma

NCT02647112 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1050

Last updated 2021-05-04

No results posted yet for this study

Summary

Clinical trial to determine the performance characteristics (sensitivity and specificity) of the Bladder EpiCheck test compared to the gold standard cystoscopy and pathology.

Conditions

Interventions

OTHER

Bladder EpiCheck

Urine test for the monitoring of bladder cancer recurrence

Sponsors & Collaborators

  • Nucleix Ltd.

    lead INDUSTRY

Principal Investigators

  • Shmulik Adler · Nucleix Ltd.

  • Fred Witjes, Prof. · Radboud University Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Germany
  • Israel
  • Netherlands
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02647112 on ClinicalTrials.gov